Close
The Serum HER-2/neu Test and Metastatic Breast Cancer
See Us Lighting Up Times Square!
During the weeks of October 12 and 26, Serum HER-2/neu will be featured on the ABC Times Square Super Sign.
Click here to view a clip[11.94 MB]
Serum HER-2/neu: Helping Women with Metastatic Breast Cancer
The Serum HER-2/neu test is a simple blood test for over 150,000 women living with metastatic breast cancer1. For the thousands of women diagnosed with metastatic breast cancer each year, the Siemens Serum HER-2/neu test is the only FDA-cleared method for monitoring their Serum HER-2/neu status during therapy. The Serum HER-2/neu test is indicated for monitoring patients with metastatic breast cancer and initial serum level >15 ng/ml.
Serum HER-2/neu Status: Providing Critical Information for Metastatic Disease Assessment
- Decreasing levels of Serum HER-2/neu reflect treatment response or disease stability. Increasing levels of Serum HER-2/neu reflect disease progression*
- Monitoring Serum HER-2/neu levels yields important information about response to therapy and cancer progression, and may help physicians make more informed decisions when developing and modifying patient treatment regimens 2-4
More information on the Serum HER-2/neu Test from Siemens:
For Patients & Caregivers
For Laboratorians
For Physicians
* For the ADVIA Centaur system a point-to-point increase or decrease of 15% reflects response or progression. For the ELISA method a point-to-point "increase or decrease of 20% reflects response or progression.
1. Silent Voices: Advanced Breast Cancer Needs Assessment Survey Report. Living Beyond Breast Cancer. 2006. Pg 1.
2. Schwartz MK, et al. International Journal of Biological Markers 2000;15(4):324.
3. Lipton A, et al. Journal of Clinical Oncology 2002;20(6):1467.
4. Esteva FJ, et al. Journal of Clinical Oncology 2002
